International Symposium - Monitoring innate immunity in arthritis and mucosal inflammation

13. – 15. April 2016, Münster, Germany

We cordially invite you to Münster for the forthcoming MIAMI (Monitoring innate immunity in arthritis and mucosal inflammation) international symposium, which will be held on April 13 – 15, 2016. The symposium is also the wrap-up meeting of the MIAMI research consortium, funded by the EU Grant HEALTH-F2-2012-305266. MIAMI‘s goal was to deliver improved and/or novel methodology for early diagnosis of disease in people at risk for seronegative arthritis, establishing a list of biomarkers indicating onset and course of inflammation. In addition, potential strategies have been devised for therapeutic intervention, including identification of potential cellular and molecular targets for treatment of the disease, with the help of SMEs.

The meeting will focus on translational approaches in seronegative arthritis and juvenile rheumatic diseases, looking at new aspects of innate immune dysregulation while employing new means for monitoring inflammation. A core aspect of the symposium will be showcasing the translation of the MIAMI Consortium scientific findings into the clinical market, also providing training sessions for clinicians.


Symposium Program

Wed 13. April 2016

All day

14.00 - 18.00    
Internal MIAMI Consortium Full Assembly

18.00 - 19.30

Welcome Reception (for all participants)

Thu 14. April 2016

08.00 - 09.00

09.00 - 10.30
Session 1 – Seronegative Arthritis: More than just Joint Inflammation
Chairs: Oliver FitzGerald, Steffen Gay
Dirk Elewaut (Ghent): Spondyloarthritis (20+5)
Oliver FitzGerald (Dublin): Psoriatic Arthritis (20+5)
Bas Vastert (Utrecht): Juvenile Idiopathic Arthritis (20+5)
Sytze de Roock (Utrecht): Discovery of biomarkers for disease progression (10+5)

10.30 - 11.00    
Coffee Break

11.00 - 12.30    
Session 2 – New Aspects of Innate Immune Dsyregulation
Chairs: Berent Prakken, Dirk Elewaut
Helena Erlandsson Harris (Stockholm): Sterile inflammation (20+5)
Thomas Pap (Munster): Inflammatory loops in mice (20+5)        
Scott Canna (Bethesda, MD): Inflammasomes and IL-18 (20+5)
Helen Cypers (Ghent): S100-DAMPs as early disease markers in preclinical stages of disease (10+5)

12.30 - 13.30
Lunch Break and Poster Viewing

13.30 - 15.30
Session 3 – New Means for Monitoring Inflammation
Chairs: Peter van Lent, Johannes Roth
Sven Hermann (Munster): Molecular imaging in clinical practice (20+5)
Min Ae Lee-Kirsch (Dresden): Interferonopathies – signatures, pathways and markers (20+5)
Matthias Gunzer (Duisburg-Essen): Imaging innate immunity in vivo (20+5)
Edwin Geven (Nijmegen): Molecular Imaging of S100-DAMPs in experimental arthritis (10+5)

15.00 - 15.30
Coffee Break

16.00 - 17.30
Session 4 – Disease Biomarkers: Omics and Beyond
Chairs: Steve Pennington, Jo Vandesompele
Steve Pennington (Dublin): Proteomic discovery and validation (20+5)
Florence Apparailly (Montpellier): MicroRNAs in rheumatoid arthritis (20+5)
Vinod Chandran (Toronto): Proteomics-based approaches in Psoriatic Arthritis (20+5)
Angela Mc Ardle (Dublin) : Unbiased identification of novel biomarkers (10+5)

Tour of the LWL-museum for art and cultural history


Fri 15. April 2016

08.30 - 10.00    
Session 5 – Innate Immunity in Mucosal Inflammation
Chairs: Torsten Kucharzik, Dirk Foell
Christoph Becker (Erlangen): Innate immune pathways in the gut (20+5)
Mathias Hornef (Aachen): Ontogeny of intestinal epithelial innate immune signalling (20+5)
Robert Colbert (Bethesda, MD): The microbiome in pediatric rheumatic diseases (20+5)
Ariane De Ganck (Ghent): Analyses of micro-RNA profiles (10+5)

10.00 - 10.30    
Coffee Break

11.00 - 12.30    
Session 6 – Juvenile Rheumatic Diseases: New Therapeutic Targets?
Chairs: Sytze de Roock, Dirk Holzinger
Dirk Holzinger (Munster): Can we predict response and outcome? (20+5)
Patrick Matthys (Leuven): Targeting Interferone-related pathways (20+5)
Alexei Grom (Cincinnati, OH): What can we learn from SJIA and MAS? (20+5)
Dirk Foell (Munster): Monitoring disease activity for individualized medicine (10+5)

12.00 - 12.30

12.30 - 14.00
Session 7 – Technical Innovation: Translation of Results into the Market
Chairs: Jakob Weber, Jo Vandesompele
Nadia Ryter (Basel): Development and validation of biomarkers for the therapy monitoring of rheumatic diseases
Jakob Weber (Basel): IBDoc® - the first CE/IVD marked home testing tool for the therapy monitoring of chronic inflammatory diseases
Jo Vandesompele (Ghent): Diagnostic potential of coding and non-coding RNAs